{"id":"imidafenacin-krp-197-ono-8025","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the M3 receptor, imidafenacin reduces bladder contractions and decreases the frequency of urge urinary incontinence episodes. This mechanism of action is specific to the M3 receptor subtype, which is primarily responsible for bladder contractions. As a result, imidafenacin provides targeted relief for patients with overactive bladder symptoms.","oneSentence":"Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:39.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder (urge urinary incontinence)"}]},"trialDetails":[{"nctId":"NCT00212706","phase":"PHASE2","title":"Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2001-10","conditions":"Overactive Bladder","enrollment":400},{"nctId":"NCT00212732","phase":"PHASE3","title":"Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2003-10","conditions":"Overactive Bladder","enrollment":750},{"nctId":"NCT00512785","phase":"PHASE3","title":"Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2007-08","conditions":"Overactive Bladder","enrollment":435}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"imidafenacin, KRP-197/ONO-8025","genericName":"imidafenacin, KRP-197/ONO-8025","companyName":"Ono Pharmaceutical Co. Ltd","companyId":"ono-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist. Used for Overactive bladder (urge urinary incontinence).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}